Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers

References

• Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. Am J Surg 1979;137:497-506
   PubMed Web of Science ®Google Scholar
• Hadaway L. Infiltration and extravasation. Preventing a complication of IV catheterization. Am J Nurs 2007;107:64-72
   PubMed Web of Science ®Google Scholar
• Liau DW. Injuries and liability related to peripheral catheters: a closed claims analysis. Available at: http://www.asahq.org/Newsletters/2006/06-06/liau06_06.html [Last accessed 25 September 2009]
   Google Scholar
• Sasson M, Shvartzman P. Hypodermoclysis: an alternative infusion technique. Am Fam Physician 2001;64:1575-8
   PubMed Web of Science ®Google Scholar
• Ferry M, Dardaine V, Constans T. Subcutaneous infusion or hypodermoclysis: a practical approach. J Am Geriatr Soc 1999;47:93-5
   PubMed Web of Science ®Google Scholar
• Farrand S, Campbell AJ. Safe, simple subcutaneous fluid administration. Br J Hosp Med 1996;55:690-2
   PubMed Web of Science ®Google Scholar
• Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37:406-9
   PubMed Web of Science ®Google Scholar
• Fudin J, Smith HS, Toledo-Binette CS, et al. Use of continuous ambulatory infusions of concentrated subcutaneous (s.q.) hydromorphone versus intravenous (i.v.) morphine: cost implications for palliative care. Am J Hosp Palliat Care 2000;17:347-53
   PubMedGoogle Scholar
• Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114:230-41
   PubMed Web of Science ®Google Scholar
• Britton RC, Habif DV. Clinical uses of hyaluronidase; a current review. Surgery 1953;33:917-42
   PubMed Web of Science ®Google Scholar
• Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-40
   PubMed Web of Science ®Google Scholar
• Hylenex (product information). Deerfield, IL: Baxter Healthcare Corporation, 2009
   Google Scholar
• Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs 2007;30:293-9
   PubMedGoogle Scholar
• Thomas JR, Yocum RC, Haller MF, et al. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 2007;10:1312-20
   PubMed Web of Science ®Google Scholar
• Thomas JR, Yocum RC, Haller MF, et al. The INFUSE-Morphine IIB Study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Manage 2009;38:673-682
   Google Scholar
• Thomas JR, Wallace MS, Yocum RC, et al. The INFUSE-Morphine Study: the use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage 2009;38:663-672
   Google Scholar
• Pirrello RD, Ting Chen C, Thomas SH. Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med 2007;10:861-4
   PubMed Web of Science ®Google Scholar
• Allen CH, Etzwiler LS, Miller MK, et al. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics 2009;124:e859-e868
   Web of Science ®Google Scholar
• Ceftriaxone (package insert). Weston, FL: Apotex Corporation, 2008
   Google Scholar
• Meyers BR, Srulevitch ES, Jacobson J, et al. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother 1983;24:812-14
   PubMed Web of Science ®Google Scholar
• Rocephine (package insert). Neuilly-sur-Seine, France: Roche Laboratories Inc., 2005
   Google Scholar
• Borner K, Lode H, Hampel B, et al. Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy 1985;31:237-45
   PubMed Web of Science ®Google Scholar
• Melin-Coviaux F, Hary L, Hurtel AS, et al. [A comparative pharmaco-clinic study of ceftriaxone after subcutaneous and intravenous administration in the elderly]. Revue de Geriatrie 2000;25:337-47
   Google Scholar
• Patel IH, Weinfeld RE, Konikoff J, et al. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother 1982;21:957-62
   PubMed Web of Science ®Google Scholar
• Hayward CJ, Nafziger AN, Kohlhepp SJ, et al. Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents. Antimicrob Agents Chemother 1996;40:485-7
   PubMed Web of Science ®Google Scholar
• Rocephin (package insert). Nutley, NJ: Roche Laboratories Inc., 2009
   Google Scholar
• Champoux N, Du SP, Ravaoarinoro M, et al. Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers. Br J Clin Pharmacol 1996;42:325-31
   PubMed Web of Science ®Google Scholar
• Bricaire F, Castaing JL, Pocidalo JJ, et al. Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration. Pathol Biol (Paris) 1988;36:702-5
   PubMed Web of Science ®Google Scholar